

No.	Name	Title of Abstract	Style	Session Name	Session Theme	Session Date	Session Time	Presentation Time	Room
10115	Yuanyuan Chen	Network-Based Metabolomic Profiling Reveals Chronic Liver Disease Progression and Identifies a Hepatocellular Carcinoma Screening Panel	Oral	IASL-APASL STC Joint Symposium	HBV Diagnosis and Treatment in Asia: From Biomarkers to the Indeterminate Grey Zone and HCC Management	Friday September 18	14:10-15:30	5min.	Room 3
10048	Emi Sometani	Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin-3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B	Oral	IASL-APASL STC Joint Symposium	HBV Diagnosis and Treatment in Asia: From Biomarkers to the Indeterminate Grey Zone and HCC Management	Friday September 18	14:10-15:30	5min.	Room 3
10277	Abdulla A. Mahmoud	Cathepsin F Supports HBV/HDV Entry into Human Hepatocytes and Represents a Promising Antiviral Target	Oral	IASL-APASL STC Joint Symposium	HBV Diagnosis and Treatment in Asia: From Biomarkers to the Indeterminate Grey Zone and HCC Management	Friday September 18	14:10-15:30	5min.	Room 3
10360	Jie Wang	Impact of Metabolic Disease Management on the Survival in Overall, HBV-related, and HCV-related Hepatocellular Carcinoma: a Real-world Cohort Study	Oral	IASL-APASL STC Joint Symposium	HBV Diagnosis and Treatment in Asia: From Biomarkers to the Indeterminate Grey Zone and HCC Management	Friday September 18	14:10-15:30	5min.	Room 3
10304	Ha H. Pham	Greyzone in Treatment-Naïve Chronic Hepatitis B Patients: Prevalence and Clinical Characteristics in a Referral Hospital in Vietnam	Oral	IASL-APASL STC Joint Symposium	HBV Diagnosis and Treatment in Asia: From Biomarkers to the Indeterminate Grey Zone and HCC Management	Friday September 18	14:10-15:30	5min.	Room 3
10077	Tomoya Hamabe	DFNA5-dependent Secondary Necrosis Drives Macrophage TNF/NF- κ B Signaling in Chronic Liver Injury	Oral	Session 02	Cutting Edge in Liver Cancer Research: Molecular Mechanisms and Therapeutic Targets	Friday September 18	9:20-10:40	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 2
10078	Naoki Tanaka	Luseogliflozin Reduces Liver Tumors in STZ/HFD Mice by Suppressing $\text{I}\text{-}\text{Trib3}\text{-}\text{I}$ Expression	Oral	Session 04	Cutting Edge in Basic Research of Steatotic Liver Diseases (MASLD/MAFLD and ALD)	Friday September 18	9:00-10:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 3
10039	Hiroki Inada	Therapeutic Activation of Wnt/ β -Catenin Signaling Accelerates Resolution of Hepatic Steatosis in MASLD Models	Oral	Session 04	Cutting Edge in Basic Research of Steatotic Liver Diseases (MASLD/MAFLD and ALD)	Friday September 18	9:00-10:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 3
10090	Yusuke Seiki	The BH3-only Protein Noxa Promotes Hepatocyte Apoptosis and Steatosis in MASLD	Oral	Session 04	Cutting Edge in Basic Research of Steatotic Liver Diseases (MASLD/MAFLD and ALD)	Friday September 18	9:00-10:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 3
10297	Taeang Arai	Optimizing FIB-4-Based Stepwise Risk Stratification in MASLD: Reducing Missed Advanced Fibrosis in Type 2 Diabetes	Oral	Session 05	Cutting-Edge Advances in the Epidemiology and Diagnosis of MASLD/MAFLD	Friday September 18	10:30-12:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 3
10147	Takuya Seike	Genetic Masking of Liver Injury: ALDH2*2 Polymorphism Uncouples Serum ALT Levels from Liver Injury in Drinkers	Oral	Session 05	Cutting-Edge Advances in the Epidemiology and Diagnosis of MASLD/MAFLD	Friday September 18	10:30-12:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 3
10200	Kazuhiro Murai	Identification of HBV Therapeutic Targets Using Primary Human Hepatocytes by Single-cell RNA Sequencing	Oral	Session 06	Cutting Edge in HBV Research: From Basic Virology to Pathogenesis	Friday September 18	14:10-15:30	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 1
10011	Takanori Suzuki	Phosphorylated Hepatitis B Core Antigen Levels Predicts Progression to Chronic Hepatitis in HBeAg-Negative Gray Zone Patients with Chronic HBV Infection	Oral	Session 07	Novel Biomarkers in HBV: Clinical Utility and Future Prospects	Friday September 18	16:55-17:55	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 1
10224	Tamami Abe	Metabolic Surgery Resolves Liver Fibrosis Independently of Steatosis in MASH: Insights from Laparoscopic Sleeve Gastrectomy	Oral	Session 08	Future Directions in the Management of MASH: Integrating Emerging and Novel Therapeutic Strategies	Friday September 18	14:15-15:30	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 2
10358	Pisit Tangkijvanich	Long-term Effects of HCV Eradication on Steatosis Progression Assessed by MRI-based Methods: The Role of Gut Microbiota and Systemic Inflammation	Oral	Session 09	HCV-Related HCC in the Post-SVR Era: Risk Assessment and Surveillance	Friday September 18	16:55-18:10	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 2

No.	Name	Title of Abstract	Style	Session Name	Session Theme	Session Date	Session Time	Presentation Time	Room
10103	Kazuma Daiku	MCL1-associated Immune Remodeling Mediates Resistance to Dual Immune Checkpoint Blockade in Hepatocellular Carcinoma	Oral	Session 10-2	Reconstructing the Treatment Landscape of Hepatocellular Carcinoma Through Systemic Therapy	Saturday September 19	11:10-12:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 1
10256	Shuntaro Obi	GALAD Maintains a High Positive-Range Classification Rate Across HCC Etiologies Despite Differences in Tumor Burden: Validation in the A-HOC Study	Oral	Session 10-2	Reconstructing the Treatment Landscape of Hepatocellular Carcinoma Through Systemic Therapy	Saturday September 19	11:10-12:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 1
10378	Takahiro Nishio	Therapeutic Control of MASLD-related HCC	Oral	Session 10-2	Reconstructing the Treatment Landscape of Hepatocellular Carcinoma Through Systemic Therapy	Saturday September 19	11:10-12:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 1
10315	Makoto Fujiya	Integrated Histologic and Imaging Features Define Morphologic Clusters Associated with Tumor Microenvironment Profiles in Advanced Hepatocellular Carcinoma	Oral	Session 10-2	Reconstructing the Treatment Landscape of Hepatocellular Carcinoma Through Systemic Therapy	Saturday September 19	11:10-12:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 1
10309	Takanori Ito	Risk Factors and Prognostic Impact of Severe Immune-Mediated Hepatotoxicity in Patients with Unresectable Hepatocellular Carcinoma Treated with Durvalumab Plus Tremelimumab	Oral	Session 10-2	Reconstructing the Treatment Landscape of Hepatocellular Carcinoma Through Systemic Therapy	Saturday September 19	11:10-12:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 1
10029	Chien-Hung Lu	Validation of the Up7-ALBI Score for Prognostication in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab	Oral	Session 10-2	Reconstructing the Treatment Landscape of Hepatocellular Carcinoma Through Systemic Therapy	Saturday September 19	11:10-12:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 1
10023	Sanae Kimura	Emergence of the HBV rtL269I Mutation and Its Contribution to Multidrug Resistance During Entecavir and Tenofovir Therapy	Oral	Session 11	Current Standards and Controversies in the Management of Chronic Hepatitis B	Saturday September 19	9:10-10:40	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 2
10250	Nobuyo Higashi-Kuwata	In Vitro Anti-Hbv Activity of a Novel Nucleoside Analog E -Cfcp Combined with an Hbv-Rna-Targeting Agent Bepirovirsen	Oral	Session 11	Current Standards and Controversies in the Management of Chronic Hepatitis B	Saturday September 19	9:10-10:40	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 2
10300	Takehisa Watanabe	Advancing SAG-524, an Oral PAPD5-Targeting Small Molecule, Toward First-in-Human Clinical Development for Functional Cure of Chronic Hepatitis B	Oral	Session 12	Novel Therapies for HBV: The Road to Functional Cure	Saturday September 19	10:50-12:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 2
10111	Osamu Yoshida	Continuous HBsAg Reduction by a Nasal Administrative Therapeutic Vaccine: The Results of 7 Years Follow Up	Oral	Session 12	Novel Therapies for HBV: The Road to Functional Cure	Saturday September 19	10:50-12:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 2
10084	Huyen D A. Tran	Cytoglobin Deficiency Accelerated LSEC Dysfunction and Tumor Progression in Diethyl Nitrosamine Treated Cytoglobin Knock-out Mice	Oral	Session 13	Cutting Edge in Cirrhosis Research: Mechanisms of Regeneration and Fibrosis Reversal	Saturday September 19	10:50-12:20	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 3
10238	Song Huy Nguyen Dinh	Liver Resection for HCC with Portal Vein Tumor Thrombosis (PVTT): Current Challenges and Long-Term Outcomes	Oral	Session 15	Frontiers of Conversion Therapy for Advanced Hepatocellular Carcinoma	Saturday September 19	13:40-15:00	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 2
10141	Asvin Selvakumar	Comparative Efficacy and Safety of Pharmacological Treatments for Primary Sclerosing Cholangitis: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials	Oral	Session 16	Cutting Edge in Autoimmune Liver Diseases (PBC/AIH/PSC): From Basic Science to Clinical Practice	Saturday September 19	13:40-14:40	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 3
10285	Akemi Tsutsui	Clinicopathological Factors Associated with Relapse during Prednisolone Therapy in Acute-Onset Autoimmune Hepatitis	Oral	Session 16	Cutting Edge in Autoimmune Liver Diseases (PBC/AIH/PSC): From Basic Science to Clinical Practice	Saturday September 19	13:40-14:40	Presentation: 8min. QA Time: 2min. Total: 10min.	Room 3